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ABSTRACT Biodegradable polylactide microparticles with encapsulated cytotoxic protein viscumin were ob-
tained via the ultrasound-assisted supercritical fluid technique. The size of the microparticles was 10–50 µM, as 
shown by electron microscopy. The time course of viscumin release from microparticles was studied using an 
immunoenzyme test system with anti-viscumin monoclonal antibodies. It was found that 99.91% of the cytotoxic 
protein was incorporated into polymer microparticles. Only 0.08% of the initially encapsulated viscumin was 
released from the microparticles following incubation for 120 h in a phosphate-buffered saline at neutral pH. 
Importantly, the method of ultrasonic dry supercritical fluid encapsulation failed to alter both the cytotoxic potency 
and the immunochemical properties of the encapsulated viscumin. Thus, this procedure can be used to generate bio-
degradable polylactide microparticles with encapsulated bioactive substances.
KEYWORDS biodegradable microparticles; viscumin; polylactide.
ABBREVIATIONS MLI – viscumin; RIP – ribosome inactivating protein; SCF – supercritical fluid; sc-CO2 – super-
critical carbon dioxide; PBS – phosphate buffered saline; TMB – tetramethylbenzidine; MSG – magnetostriction 
generator; SEM – scanning electron microscopy; BSA – bovine serum albumin; MTT – 3-(4,5-dimethylthiozolyl-
2-yl)-2,5-diphenyltetrazolium bromide; LD50 – lethal dose for 50% of the cells.
INTRODUCTION
Viscumin, a ribosome-inactivating lectin, occurs in leaf 
extracts from the parasitic plant common Mistletoe 
(Viscum album). Viscumin has a molecular weight of 
60 kDa and consists of two subunits, A and B, which 
are linked via a disulfide bond [1, 2]. this protein has 
found widespread application in anti-tumor therapy 
[3–6]. Its efficacy can be enhanced by encapsulating 
viscumin into biodegradable polymer microparticles, 
thus ensuring its chemical and spatial stabilization, as 
well as a prolonged release of the protein into the sur-
rounding tissues. Hence, the toxin will have a prolonged 
effect on tumor cells.
Polylactides are a class of biodegradable polymers 
that belong to the homologous series of aliphatic poly-
esters that are finding increased application in biomed-
icine and pharmaceutics [7]. Polylactide is a polymer 
of lactic acid that contains asymmetric carbon atoms 
(Fig. 1) and can easily form optically active cyclic dim-
ers (lactides), which are capable of polymerizing via 
catalytic opening of 1,4-dioxane rings, similar to the 
polymerization of glycolides.
Polylactide contains methyl groups, and thus it is 
a more hydrophobic compound as compared to poly-
glycolide. Polyactide dissolves more easily in organic 
solvents. Since a monomer of lactic acid exists in two 
stereometric forms, four morphologically different 
polylactides can be synthesized: two stereo-regular 
polymers, poly(D-lactide) and poly(L-lactide); a polym-
erized blend of the D- and L-lactic acids – poly(D,L-
lactide); and poly(meso-lactide) – D- and L-lactide 
blends. the polymers synthesized from the optically ac-
tive D- or L-lactic acid only are polycrystalline, where-
as the optically inactive poly(D,L-lactides) possess an 
amorphous structure. this fact is significant in their 
practical application, since the hydrolysis rate of these 
compounds (which determines their biodegradation 
kinetics in a living organism) is inversely proportional 
to their degree of crystallinity. Glycolide is a simpler 
compound that exists only in single form. the identity 102 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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of the catalytic reaction of ring opening in glycolides 
and lactides enables copolymerization, yielding high-
molecular-weight copolymers (polylactoglycolides); this 
fact considerably broadens the range of biodegradable 
synthetic materials that possess various biochemical 
and mechanical properties.
the ability of aliphatic polyesters to gradually bio-
degrade in the organism is used both to provide tem-
porary protection to active molecules or drugs against 
rapid degradation by various enzymes and peptides 
and for the targeted delivery of these compounds to 
specific cells, tissues, and organs, as well as to control 
the release rate of these molecules from the polymer 
matrix, thus ensuring a more prolonged therapeutic 
effect [7]. For this purpose, a drug is encapsulated 
into a polymer carrier and is injected or introduced 
perorally into the organism [8, 9]. the method of dry 
supercritical fluid (ScF) encapsulation can be success-
fully used to incorporate various biologically active 
compounds (enzymes, peptides, proteins, and drugs) 
into polymer microparticles, the physicochemical and 
biological properties of which are almost complete-
ly retained [10–12]. this fact serves to differentiate 
ScF encapsulation from other methods, whose appli-
cation assumes the use of high temperatures (up to 
100°c and even higher) and toxic organic solvents; it 
is rather problematic to remove these solvents from 
the final product [10]. Supercritical carbon dioxide (sc-
cO2) allows one to perform the encapsulation of bio-
active components into various amorphous polymers 
without using liquid solvents at temperatures close to 
room temperature and under moderate pressure (the 
critical parameters for cO2: Тcr = 31°c, Рcr = 7.4 МПа). 
Sc-cO2 can be easily and almost completely removed 
from the polymer by reducing pressure below the 
critical value [13].
the first model experiments devoted to the ScF en-
capsulation of viscumin into polylactide micromatrices 
were performed earlier [11]. It was revealed that the 
liberation time of viscumin can be controlled by vary-
ing the conditions of ScF encapsulation. this procedure 
actually enables the design of prolonged-action drugs 
with the desired release kinetics of the active substance 
from the polymer carrier.
Herein, the immunochemical and cytotoxic proper-
ties of viscumin, following its liberation from micropar-
ticles produced via the same procedure but with the 
use of ultrasound, were studied. Denser, fine particles 
(10–50 µm) were obtained using ultrasound.
EXPERIMENTAL
Viscumin was kindly provided by Professor u. Pfüller 
(Institute of Phytochemistry, university of Witten/
Herdecke, Germany). D,L-polylactide PurASOrB 
PDL 02 (PurAc Biochem bv, netherlands) with a 
molecular mass Mw ~ 20000 was used as an initial bio-
degradable polymer. carbon dioxide of special purity 
grade (99.99%, Balashikha Oxygen Plant, Moscow ob-
last, russia) was used without any additional purifica-
tion. Dry phosphate buffered saline (PBS, Flow Labo-
ratories, Great Britain), two-component reagent kit for 
the substrate mixture based on tetramethylbenzidine 
(tMB) for eLISA and the streptavidin–peroxidase con-
jugate (IMteK, russia); and polystyrene plates (costar, 
uSA) were also used. Monoclonal antibodies MnA4 and 
biotinylated MnA9 against various epitopes of the vis-
cumin A-subunit were obtained earlier [14, 15]. the re-
maining reagents were purchased from Sigma-Aldrich 
corporation (uSA).
Encapsulation of viscumin into 
polylactide microparticles
the encapsulation of viscumin into the polylactide car-
rier was performed on an experimental setup similar 
to that described in [16]. the major difference from 
the previously used equipment [11] was the power-
ful ultrasonic action (18 ± 0.2 kHz, up to 1 kW that the 
polymer/viscumin system in sc-cO2 atmosphere was 
subjected to). this approach was implemented using 
a magnetostriction generator (MSG) with an acoustic 
concentrator and titanium inducer introduced into the 
high-pressure reaction chamber.
the formation of bioactive microparticles is at-
tained via the following steps: the powder-like 
polylactide with a characteristic particle size of 100–
200 µm (0.1 g) produced from preliminarily grinded 
initial polymer grains with a diameter of ~ 3÷4 mm 
L-lactide  Meso-lactide
Glycolide  D,L-lactide
Fig. 1. Cyclic dimers for the synthesis ofaliphatic polyes-
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and lyophilized viscumin powder (1 mg) were loaded 
into the high-pressure reaction chamber. the cham-
ber was pressurized; cO2 at room temperature was 
fed until the pressure reached 5 MPa. the chamber 
heaters and nozzles were subsequently turned on. the 
temperature in the chamber was typically at 40оС; 
the nozzle temperature varied from 40 to 80оС. the 
pressure in the chamber increased with each rise in 
temperature. After the desired temperature was at-
tained, the pressure in the chamber was brought to 
a pre-selected value of 10 ÷ 20 MPa. the MSG power 
control unit was then turned on; its power was varied 
within a range of 0.1–1.0 kW. the system was kept un-
der these conditions for ~ 30 min to form the regime of 
ScF plasticization of the viscumin–polymer mixture 
in the reactor. A pulsed discharge of the plasticized 
mixture and carbon dioxide into the inlet chamber 
was subsequently performed using a pulsed valve, via 
a 0.5 mm diameter nozzle.
After the resulting product was stored in the inlet 
chamber under atmospheric conditions for 3 h (the time 
required for the complete removal of cO2 from polymer 
particles and the final hardening of the particles), the 
microparticles being collected were placed into 1.5 ml 
glass vials and were stored at a temperature of +4°c 
prior to the subsequent analysis.
Scanning electron microscopy
the morphology of the surface of the polymer micro-
particles with viscumin encapsulated via the sc-cO2 
technique was studied using scanning electron micros-
copy (SeM) on a LeO 1450 microscope (carl Zeiss, Ger-
many). A small amount of the powder under study was 
applied on a conducting (carbon) adhesive tape with a 
thin (~ 0.05–0.1 µm) gold film, which was coated onto 
it via plasma spraying and ensured the required con-
ductivity.
Investigation of the time course of viscumin 
liberation from polylactide microparticles
A dry powder of viscumin-containing polylactide mi-
croparticles (16.5 mg) was suspended in 2 ml of PBS; 
the suspension was centrifuged for 10 min at 12,100 g; 
and the supernatant was then sampled. the remaining 
polylactide particles were again suspended in 2 ml of 
PBS and then stirred on a rocker at 22°c. the superna-
tant was sampled, and the next PBS portion was added 
after 10, 30, 60, 120, 360, 1440, 2880, and 7200 min, re-
spectively. the resulting samples were stored at +4°c.
Analysis of the amount of viscumin liberated 
upon degradation of polylactide microparticles
the amount of viscumin in the samples (i.e., in the su-
pernatant sampled at different time points) was deter-
mined using the earlier described modified test system 
[14, 15]. Anti-viscumin monoclonal antibodies MnA4 
at a concentration of 10 µg/ml in PBS were adsorbed 
onto a 96-well plate (100 µl per well). the antibod-
ies were incubated for 24 h at +4°С and subsequently 
washed with a solution containing 20 mmol/l lactose 
and 0.05% tween 20 in PBS. 100 µl of the buffer solu-
tion containing 0.1% of bovine serum albumin (BSA), 
20 mmol/l lactose and 0.05% of tween 20 in PBS were 
introduced into each well to block the vacant binding 
sites of the polystyrene surface. Following incubation 
for 1 h at 37°С, the antibodies were washed three times 
and 100 µl of the viscumin-containing samples under 
study in various dilutions were added to each well. Vis-
cumin at different concentrations was used as a con-
trol sample. the incubation was performed for 1 h at 
37°С. Biotin-labelled anti-viscumin monoclonal anti-
bodies MnA9 at a concentration of 2 µg/µl were then 
applied. the following procedure included incubation 
for 1 h at 37°С, threefold washing, and incubation (1 h, 
37°С) with the streptavidin–peroxidase conjugate and 
fivefold washing. the development was carried out for 
20 min at 37°С using a tMB substrate buffer. the reac-
tion was stopped by adding 50 µl of 10% sulfuric acid 
to each well. colorimetric measurements were carried 
out on a Multiskan® PLuS-314 spectrophotometer at 
450 nm.
the amount of viscumin incorporated into the mi-
croparticles was determined via solid-phase eLISA 
according to the above-described scheme. For this 
purpose, the sample of polylactide microparticles was 
completely hydrolyzed at 420С for 48 h (5 mg of the 
sample in 10 ml PBS).
Evaluation of the cytotoxic properties of viscumin 
following its release from polylactide microparticles
the cytotoxic activity of viscumin liberated from bi-
opolymer microparticles was determined using the 
Mtt assay according to the earlier described proce-
dure [17, 18]. the lethal dose of toxin (viscumin) for 50% 
of the cells (LD50) was determined to assess the survival 
rate of the cells. Viscumin not subjected to encapsula-
tion was used as the control. When calculating LD50, the 
staining intensity of the cells cultured in the absence of 
a cytotoxic agent was assumed to be 100%. the results 
obtained in one of three typical experiments are pre-
sented (LD50 ± standard deviation).
RESULTS AND DISCUSSION
the typical SeM microimages of the experimental 
samples after their removal from the inlet chamber 
of the ScF setup are shown in Fig. 2. It is clear that 
the samples consist both of individual microparticles 
(10–50 µm) and particle agglomerates (up to 200 µm). 104 | ActA nAturAe |  VOL. 4  № 1 (12)  2012
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Polylactide microparticles are dense bulk particles of 
irregular shape with an appreciably smooth surface.
the use of a powerful ultrasonic action made it 
possible not only to achieve more homogeneous stir-
ring of the initial components (viscumin and polylac-
tide), but to considerably reduce the viscosity of the 
polymer plasticized in sc-cO2 due to the introduction 
of additional acoustic energy to the system, as well. 
the combination of these factors resulted in a cardi-
nal change in the regime of subsequent dispersion of 
the resulting mixture into the inlet chamber under 
atmospheric pressure. In turn, the morphology of the 
bioactive polymer structures being formed drastically 
changed.
thus, polylactide fibrous matrices consisting of po-
rous microparticles of irregular shape (50–200 µm) 
formed when the magnetic stirrer was used alone un-
der the same conditions [11]. Meanwhile, the use of 
intensive acoustic action resulted in the formation of 
dense individual microparticles with the characteristic 
size varying from 10 to 50 µm.
the previously described test system based on the 
monoclonal anti-viscumin antibodies MnA4 and bi-
otinylated MnA-9 [14, 15] was used to determine the 
amount of viscumin in the samples. the system ena-
bles the specific determination of viscumin; its sensi-
tivity threshold is approximately 0.8 ng/ml. the to-
tal amount of viscumin in a 5 mg sample consisting 
of polylactide particles was assessed using this test 
system. the total amount of viscumin appeared to be 
equal to 50 µg, which corresponds to 1 wt % and rep-
resents the amount of viscumin subjected to encap-
sulation. Presumably, this attests to the fact that the 
protein antigenic structure after the encapsulation 
remained unchanged.
It is reasonable to assume that some nonencapsulated 
viscumin could remain on the microparticle surface. In 
order to remove the unbound viscumin, 16.5 mg of the 
microparticles was washed twice in PBS (time points 
0 and 10 min). the amount of viscumin in these sam-
ples was 0.145 µg (i.e., 0.09% of the total amount of the 
toxin subjected to encapsulation). thus, the amount of 
encapsulated viscumin was equal to 99.91%. Figures 3A 
and 3B show the amount of viscumin liberated from 
polylactide microparticles during a period from 0 to 
120 h.
It is clear from Fig. 3B that the toxin amount in su-
pernatants decreased with incubation time. this fact 
indicates the slow degradation of polymer microparti-
cles with the gradual release of viscumin. An increase 
in the amount of viscumin in supernatants at points 6 
and 24 h can be explained by longer incubation, when a 
greater amount of toxin is liberated from the degraded 
polymer. In addition, starting at point 48 h, viscumin 
was released more slowly. this type of kinetics of toxin 
release may be linked with the structure of polylactide 
microparticles; i.e., inside a microparticle it is denser 
than outside. A total of 0.134 µg of viscumin was re-
leased from the polylactide matrix after 120 h (except 
for the amount of viscumin detected in the samples af-
ter they were washed twice), which is equal to 0.08% of 
the initially encapsulated protein.
Viscumin belongs to type II ribosome-inactivating 
proteins; it can be used to remove eukaryotic target 




 VOL. 4  № 1 (12)  2012  | ActA nAturAe | 105
Fig. 3. Kinetics of the release of viscumin from polylactide 
microparticles. (A) – the overall amount of viscumin in the 
supernatants under analysis. (B) – the amount of viscumin 






















































































cells [19–21]. It was demonstrated using the Mtt as-
say that viscumin retains its cytotoxic activity after 
it is released from polylactide microparticles. the cy-
totoxic activity of viscumin in supernatants remained 
virtually the same as that of the untreated toxin: the 
concentration of the native viscumin causing the death 
of 50% of 3t3 cells (LD50) after 48 h was equal to 7 × 10-
12 ± 3 × 10-12 М; LD50 of viscumin in the samples under 
analysis was equal to 7 × 10-12 ± 2 × 10-12 М.
It should be mentioned that the morphology of the 
surface and internal structure of the polymer micro-
particles being formed can be varied over an appreci-
ably wide range (from highly porous to virtually mono-
lithic) by changing the regimes of ScF encapsulation 
and sputtering of the plasticized polymer blend; this 
will have a determining effect on the kinetics of release 
of bioactive components from these particles. the re-
sults obtained clearly demonstrated this fact. thus, the 
viscumin-containing polylactide structures in [11] were 
represented by agglomerates of porous particles (with a 
characteristic porosity coefficient of 20–25%) of irregu-
lar shape, as opposed to the dense microparticles with 
smooth surfaces, obtained in the present work (Figs. 3A 
and 3B). correspondingly, the kinetics of viscumin re-
lease from these structures under identical conditions 
(suspension in PBS, slow stirring on a rocker at 22°c; 
samples were collected after two washings and after 
30, 60, 120, 360, 1440, 2880, and 7220 min) was cardi-
nally different from that shown in Fig. 3A.
Viscumin can be used in anti-tumor therapy [22]. 
the application of biocompatible biodegradable sys-
tems containing slowly releasing viscumin has consid-
erable potential. Drug introduction via injection into 
the area of tumor growth becomes less traumatic due 
to the reduction in the size of the biodegradable micro-
particles containing viscumin and/or another specific 
anti-tumor cytotoxin.
the ultrasound-assisted technique of dry supercriti-
cal fluid encapsulation does not affect the cytotoxic and 
immunochemical properties of the viscumin incorpo-
rated into polylactide microparticles. the designed en-
capsulation technique ensures the gradual release of 
the encapsulated toxin from microparticles, which can 
provide a more prolonged therapeutic effect.   
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